Global Octreotide Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Octreotide Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Dec 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Global Octreotide Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the Global Octreotide Market size in 2022 - 3.00 and 2030 - 3.80, highlighting the projected market growth. USD 3.00 Billion USD 3.80 Billion 2022 2030
Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 3.00 Billion
Diagram Market Size (Forecast Year)
USD 3.80 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • China National Pharmaceutical Group Corporation
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Shanghai Soho-Yiming Pharmaceuticals Co.Ltd.

Global Octreotide Market, By Type (octreotide acetate, octreotide, octreotide chloride, octreotide hydrochloride, indium In-111; octreotide), Form (Injection, Powder, Microspheres), Indications (Diarrhoea, Acromegaly, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Octreotide Market

Octreotide Market Analysis and Size

Growing incidence of disease such as acromegaly and cancer, is anticipated to surge the demand for octreotide drugs, which in turn is expected to drive the market growth. The demand is greatly increased by increasing number of people under the diagnosis of cancer. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the U.S. The growing popularity of generic drugs might affect the consumption of branded drugs.

Data Bridge Market Research analyses a growth rate in the octreotide market in the forecast period 2023-2030. The expected CAGR of octreotide market is tend to be around 3% in the mentioned forecast period. The market was valued at USD 3 billion in 2022, and it would grow upto USD 3.80 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Octreotide Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (octreotide acetate, octreotide, octreotide chloride, octreotide hydrochloride, indium In-111; octreotide), Form (Injection, Powder, Microspheres), Indications (Diarrhoea, Acromegaly, Others), End-Users (Veterinary Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), China National Pharmaceutical Group Corporation (China), Sihuan Pharmaceutical Holdings Group Ltd (China), Shanghai Soho-Yiming Pharmaceuticals Co.,Ltd. (China)

Market Opportunities

  • Growing Drug Launches
  • Increasing Rates of Cancer

Market Definition

Octreotide is a type of hormone drug which is used to treat some types of cancer. It is sold under the brand name Sandostatin among others and is a long-acting injection used to control acromegaly and carcinoid tumours in people. This class of medications is also known as octapeptides. This medication is also used to treat extreme watery diarrhoea and sudden reddening of the face. This medication works by hindering the production of natural substances hormones.  

Octreotide Market Dynamics

Drivers

  • Increasing Pipeline of Drugs

The robust pipeline of drugs in clinical trials is expected to boost the market growth. For instance, in 2016, Mario Negri Institute for pharmacological research completed phase 2 clinical trials of its Octreotide LAR along with tolvaptan drug used for the treatment of autosomal dominant polycystic kidney disease. Octreotide sponsored by Radbound University is in phase 3 clinical trials from 2016. This drug is under clinical trial for the treatment of vascular malformations, angiodysplasia, gastrointestinal hemorrhage, and anemia with octreotide. Injection Octreotide, which is sponsored by PVS memorial hospital is in phase 4 clinical trials since 2016. This injection is precisely used for treatment of pancreatic fistula and complications of pancreatoduodenectomy among patients with soft pancreas. Moreover, CAM2029 is being tested, that is currently in phase 2, for acromegaly and neuroendocrine tumors by Camurus AB in collaboration with Novartis AG. Octreotide chloride is the active ingredient for this product.

Opportunities

  • Growing Drug Launches

A growing number of launches relating to novel Octreotide acetate products by major market players is anticipated to drive market growth. For instance, in 2013, Sagent Pharmaceuticals, which is a U.S.-based biopharmaceutical company, launched its new drug Octreotide acetate, a samatostatin analog. This drug is used to decrease blood levels of IGF-I and growth hormone in acromegaly patients who do not sufficiently respond to or who cannot be treated by surgery, irradiation and bromocriptine mesylate.

  • Increasing Rates of Cancer

The global demand for octreotide is boosted by increasing number of people under the diagnosis of cancer. In 2012, there were projected 14.1 million cases of cancer .It is expected that by 2035, the number of people surviving from cancer will be about 24 million. These estimate shows that the demand for treatment drugs such as octreotide will grow. It is estimated that about 2200 children die every day because of severe diarrhea, more than Aids, malaria and measles combined.

 Restraints/Challenges

  • High Cost of Treatment

The enormous expenditure associated with the treatment of octreotide impede the market growth. The treatment becomes quite unaffordable in middle-income countries, thus, in a way limiting the market growth.

This octreotide market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the octreotide market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Global Octreotide Market Scope

The octreotide market is segmented on the basis of type, form, indications, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • octreotide acetate
  • octreotide
  • octreotide chloride
  • octreotide hydrochloride
  • indium In-111; octreotide

Form

  • Injection
  • Powder
  • Microspheres

Indications

  • Diarrhoea
  • Acromegaly
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Octreotide Market Regional Analysis/Insights

The octreotide market is analyzed and market size insights and trends are provided by type, form, indications, distribution channel and end-user as referenced above.

The major countries covered in the octreotide market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for octreotide market throughout the forecasted period due to increased new research and developments on octreotide market.  

North America dominates the market due to the presence of key manufacturers of the product is high and, increasing research and development activities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Octreotide Market Share Analysis

The octreotide market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to octreotide market.

Key players operating in the octreotide market include:

  • Novartis AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • China National Pharmaceutical Group Corporation (China)
  • Sihuan Pharmaceutical Holdings Group Ltd (China)
  • Shanghai Soho-Yiming Pharmaceuticals Co.,Ltd. (China)
  • JB Pharma (India)
  • Samarth Life Sciences Pvt. Ltd. (India)

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL OCTREOTIDE MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL OCTREOTIDE MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY MODELING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL OCTREOTIDE MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 IP STRATEGY AND MANAGEMENT

7.6 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNONLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 NUMBER OF PRODUCTS IN DEVELOPMENT

10.3 STAGE OF DEVELOPMENT

10.4 TIMELINES AND MILESTONES

10.5 INNOVATION STRATEGIES AND METHODOLOGIES

10.6 RISK ASSESSMENT AND MITIGATION

10.7 MERGERS AND ACQUISITIONS

10.8 FUTURE OUTLOOK

11 EPIDEMIOLOGY

11.1 INCIDENCE OF ALL BY GENDER

11.2 TREATMENT RATE

11.3 MORTALITY RATE

11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

11.5 PATIENT TREATMENT SUCCESS RATES

12 REGULATORY COMPLIANCE

12.1 REGULATORY AUTHORITIES

12.2 REGULATORY CLASSIFICATIONS

12.2.1 CLASS I

12.2.2 CLASS II

12.2.3 CLASS III

12.3 REGULATORY SUBMISSIONS

12.4 INTERNATIONAL HARMONIZATION

12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

12.6 REGULATORY CHALLENGES AND STRATEGIES

13 PIPELINE ANALYSIS

13.1 CLINICAL TRIALS AND PHASE ANALYSIS

13.2 DRUG THERAPY PIPELINE

13.3 PHASE III CANDIDATES

13.4 PHASE II CANDIDATES

13.5 PHASE I CANDIDATES

13.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR OCTREOTIDE MARKET

Company Name Product Name

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR OCTREOTIDE MARKET

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved but Not Yet Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR OCTREOTIDE MARKET

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR OCTREOTIDE MARKET

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR OCTREOTIDE MARKET

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

14 REIMBURSEMENT FRAMEWORK

15 OPPUTUNITY MAP ANALYSIS

16 VALUE CHAIN ANALYSIS

17 HEALTHCARE ECONOMY

17.1 HEALTHCARE EXPENDITURE

17.2 CAPITAL EXPENDITURE

17.3 CAPEX TRENDS

17.4 CAPEX ALLOCATION

17.5 FUNDING SOURCES

17.6 INDUSTRY BENCHMARKS

17.7 GDP RATION IN OVERALL GDP

17.8 HEALTHCARE SYSTEM STRUCTURE

17.9 GOVERNMENT POLICIES

17.1 ECONOMIC DEVELOPMENT

18 GLOBAL OCTREOTIDE MARKET, BY TYPE

18.1 OVERVIEW

18.2 OCTREOTIDE

18.3 OCTREOTIDE ACETATE

18.4 OCTREOTIDE CHLORIDE

18.5 OCTREOTIDE HYDROCHLORIDE

18.6 INDIUM IN-111 OCTREOTIDE

19 GLOBAL OCTREOTIDE MARKET, BY FORM

19.1 OVERVIEW

19.2 SHORT ACTING FORMULATION

19.3 LONG-ACTING FORMULATION

20 GLOBAL OCTREOTIDE MARKET, BY DOSAGE STRENGTH

20.1 OVERVIEW

20.2 CAPSULE MYCAPSSA - 20MG

20.3 INJECTABLE SOLUTION (SANDOSTATIN)

20.3.1 0.05MG/ML

20.3.2 0.1MG/ML

20.3.3 0.2MG/ML

20.3.4 0.5MG/ML

20.3.5 1MG/ML

20.4 DEPOT INJECTION (SANDOSTATIN LAR DEPOT)

20.4.1 10MG/KIT

20.4.2 20MG/KIT

20.4.3 30MG/KIT

20.5 OTHERS

21 GLOBAL OCTREOTIDE MARKET, BY DRUG TYPE

21.1 OVERVIEW

21.2 BRANDED

21.2.1 BYNFEZIA

21.2.2 SANDOSTATIN

21.2.3 SANDOSTATIN LAR DEPOT

21.2.4 OTHERS

21.3 GENERICS

22 GLOBAL OCTREOTIDE MARKET, ROUTE OF ADMINISTRATION

22.1 OVERVIEW

22.2 ORAL

22.2.1 CAPSULES

22.2.2 OTHERS

22.3 PARENTERAL

22.3.1 BY FORM

22.3.1.1. INJECTION

22.3.1.2. POWDER

22.3.1.3. MICROSPHERES

22.3.2 BY SITE

22.3.2.1. INTRAVENEOUS

22.3.2.2. SUBCUTANEOUS

22.4 OTHERS

23 GLOBAL OCTREOTIDE MARKET, BY POPULATION TYPE

23.1 OVERVIEW

23.2 PEDIATRIC

23.3 ADULTS

23.4 GERIATRIC

24 GLOBAL OCTREOTIDE MARKET, BY GENDER

24.1 OVERVIEW

24.2 MALE

24.2.1 PEDIATRIC

24.2.2 ADULTS

24.2.3 GERIATRIC

24.3 FEMALE

24.3.1 PEDIATRIC

24.3.2 ADULTS

24.3.3 GERIATRIC

25 GLOBAL OCTREOTIDE MARKET, BY APPLICATION

25.1 OVERVIEW

25.2 CANCER

25.2.1 CARCINOID SYNDROME

25.2.2 NEUROENDOCRINE TUMOURS (NETS)

25.2.3 OTHERS CANCER

25.3 ESOPHAGEAL VARICEAL BLEEDING

25.4 DIARRHOEA

25.5 ACROMEGALY

25.6 OTHERS

26 GLOBAL OCTREOTIDE MARKET, BY END USER

26.1 OVERVIEW

26.2 HOSPITALS

26.2.1 PUBLIC

26.2.2 PRIVATE

26.3 SPECIALTY CLINICS

26.4 HOME HEALTHCARE

26.5 ACADEMIC AND RESEARCH INSTITUTE

26.6 OTHERS

27 GLOBAL OCTREOTIDE MARKET, BY DISTRIBUTION CHANNEL

27.1 OVERVIEW

27.2 DIRECT TENDER

27.3 RETAIL SALES

27.3.1 HOSPITAL PHARMACIES

27.3.2 DRUG STORES

27.3.3 PHARMACY CHAINS

27.3.4 ONLINE PHARMACIES

27.3.4.1. E-PHARMACY COMPANIES

27.3.4.2. COMPANY OWNED E-PHARMACY

27.4 OTHERS

28 GLOBAL OCTREOTIDE MARKET, BY GEOGRAPHY

GLOBAL OCTREOTIDE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

28.1 NORTH AMERICA

28.1.1 U.S.

28.1.2 CANADA

28.1.3 MEXICO

28.1.4 DOMINICAN REPUBLIC

28.1.5 JAMAICA

28.1.6 PANAMA

28.2 EUROPE

28.2.1 GERMANY

28.2.2 FRANCE

28.2.3 U.K.

28.2.4 HUNGARY

28.2.5 LITHUANIA

28.2.6 AUSTRIA

28.2.7 IRELAND

28.2.8 NORWAY

28.2.9 POLAND

28.2.10 ITALY

28.2.11 SPAIN

28.2.12 RUSSIA

28.2.13 TURKEY

28.2.14 NETHERLANDS

28.2.15 SWITZERLAND

28.2.16 REST OF EUROPE

28.3 ASIA-PACIFIC

28.3.1 JAPAN

28.3.2 CHINA

28.3.3 TAIWAN

28.3.4 SOUTH KOREA

28.3.5 INDIA

28.3.6 AUSTRALIA

28.3.7 SINGAPORE

28.3.8 THAILAND

28.3.9 MALAYSIA

28.3.10 INDONESIA

28.3.11 PHILIPPINES

28.3.12 VIETNAM

28.3.13 REST OF ASIA-PACIFIC

28.4 SOUTH AMERICA

28.4.1 BRAZIL

28.4.2 ECUADOR

28.4.3 CHILE

28.4.4 COLOMBIA

28.4.5 VENEZUELA

28.4.6 ARGENTINA

28.4.7 PERU

28.4.8 CURAÇAO

28.4.9 PARAGUAY

28.4.10 URUGUAY

28.4.11 TRINIDAD AND TOBAGO

28.4.12 REST OF SOUTH AMERICA

28.5 MIDDLE EAST AND AFRICA

28.5.1 SOUTH AFRICA

28.5.2 SAUDI ARABIA

28.5.3 UAE

28.5.4 EGYPT

28.5.5 KUWAIT

28.5.6 ISRAEL

28.5.7 BOLIVIA

28.5.8 REST OF MIDDLE EAST AND AFRICA

28.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

29 GLOBAL OCTREOTIDE MARKET, SWOT AND DBMR ANALYSIS

30 GLOBAL OCTREOTIDE MARKET, COMPANY LANDSCAPE

30.1 COMPANY SHARE ANALYSIS: GLOBAL

30.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

30.3 COMPANY SHARE ANALYSIS: EUROPE

30.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

30.5 MERGERS & ACQUISITIONS

30.6 NEW PRODUCT DEVELOPMENT & APPROVALS

30.7 EXPANSIONS

30.8 REGULATORY CHANGES

30.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

31 GLOBAL OCTREOTIDE MARKET, COMPANY PROFILE

31.1 NOVARTIS AG

31.1.1 COMPANY OVERVIEW

31.1.2 REVENUE ANALYSIS

31.1.3 GEOGRAPHIC PRESENCE

31.1.4 PRODUCT PORTFOLIO

31.1.5 RECENT DEVELOPMENTS

31.2 GLAND PHARMA LIMITED

31.2.1 COMPANY OVERVIEW

31.2.2 REVENUE ANALYSIS

31.2.3 GEOGRAPHIC PRESENCE

31.2.4 PRODUCT PORTFOLIO

31.2.5 RECENT DEVELOPMENTS

31.3 AVET PHARMACEUTICALS INC.

31.3.1 COMPANY OVERVIEW

31.3.2 REVENUE ANALYSIS

31.3.3 GEOGRAPHIC PRESENCE

31.3.4 PRODUCT PORTFOLIO

31.3.5 RECENT DEVELOPMENTS

31.4 USV PRIVATE LIMITED

31.4.1 COMPANY OVERVIEW

31.4.2 REVENUE ANALYSIS

31.4.3 GEOGRAPHIC PRESENCE

31.4.4 PRODUCT PORTFOLIO

31.4.5 RECENT DEVELOPMENTS

31.5 SUN PHARMACEUTICAL INDUSTRIES LTD.

31.5.1 COMPANY OVERVIEW

31.5.2 REVENUE ANALYSIS

31.5.3 GEOGRAPHIC PRESENCE

31.5.4 PRODUCT PORTFOLIO

31.5.5 RECENT DEVELOPMENTS

31.6 VIATRIS INC.

31.6.1 COMPANY OVERVIEW

31.6.2 REVENUE ANALYSIS

31.6.3 GEOGRAPHIC PRESENCE

31.6.4 PRODUCT PORTFOLIO

31.6.5 RECENT DEVELOPMENTS

31.7 FRESENIUS KABI USA

31.7.1 COMPANY OVERVIEW

31.7.2 REVENUE ANALYSIS

31.7.3 GEOGRAPHIC PRESENCE

31.7.4 PRODUCT PORTFOLIO

31.7.5 RECENT DEVELOPMENTS

31.8 WEST-WARD PHARMACEUTICALS CORP.

31.8.1 COMPANY OVERVIEW

31.8.2 REVENUE ANALYSIS

31.8.3 GEOGRAPHIC PRESENCE

31.8.4 PRODUCT PORTFOLIO

31.8.5 RECENT DEVELOPMENTS

31.9 SAGENT PHARMACEUTICALS

31.9.1 COMPANY OVERVIEW

31.9.2 REVENUE ANALYSIS

31.9.3 GEOGRAPHIC PRESENCE

31.9.4 PRODUCT PORTFOLIO

31.9.5 RECENT DEVELOPMENTS

31.1 REWINE PHARMACEUTICAL

31.10.1 COMPANY OVERVIEW

31.10.2 REVENUE ANALYSIS

31.10.3 GEOGRAPHIC PRESENCE

31.10.4 PRODUCT PORTFOLIO

31.10.5 RECENT DEVELOPMENTS

31.11 SANJAR PHARMA LLP

31.11.1 COMPANY OVERVIEW

31.11.2 REVENUE ANALYSIS

31.11.3 GEOGRAPHIC PRESENCE

31.11.4 PRODUCT PORTFOLIO

31.11.5 RECENT DEVELOPMENTS

31.12 AMRYT PHARMA PLC (CHIESI FARMACEUTICI S.P.A.)

31.12.1 COMPANY OVERVIEW

31.12.2 REVENUE ANALYSIS

31.12.3 GEOGRAPHIC PRESENCE

31.12.4 PRODUCT PORTFOLIO

31.12.5 RECENT DEVELOPMENTS

31.13 CHIASMA, INC. + LONZA

31.13.1 COMPANY OVERVIEW

31.13.2 REVENUE ANALYSIS

31.13.3 GEOGRAPHIC PRESENCE

31.13.4 PRODUCT PORTFOLIO

31.13.5 RECENT DEVELOPMENTS

31.14 NEISS LABS LTD.

31.14.1 COMPANY OVERVIEW

31.14.2 REVENUE ANALYSIS

31.14.3 GEOGRAPHIC PRESENCE

31.14.4 PRODUCT PORTFOLIO

31.14.5 RECENT DEVELOPMENTS

31.15 SAMARTH LIFE SCIENCES PVT. LTD.

31.15.1 COMPANY OVERVIEW

31.15.2 REVENUE ANALYSIS

31.15.3 GEOGRAPHIC PRESENCE

31.15.4 PRODUCT PORTFOLIO

31.15.5 RECENT DEVELOPMENTS

31.16 SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.

31.16.1 COMPANY OVERVIEW

31.16.2 REVENUE ANALYSIS

31.16.3 GEOGRAPHIC PRESENCE

31.16.4 PRODUCT PORTFOLIO

31.16.5 RECENT DEVELOPMENTS

31.17 SHANGHAI SOHO-YIMING PHARMACEUTICALS CO.,LTD. (ANKEBIO)

31.17.1 COMPANY OVERVIEW

31.17.2 REVENUE ANALYSIS

31.17.3 GEOGRAPHIC PRESENCE

31.17.4 PRODUCT PORTFOLIO

31.17.5 RECENT DEVELOPMENTS

31.18 CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY CO.,LTD.

31.18.1 COMPANY OVERVIEW

31.18.2 REVENUE ANALYSIS

31.18.3 GEOGRAPHIC PRESENCE

31.18.4 PRODUCT PORTFOLIO

31.18.5 RECENT DEVELOPMENTS

31.19 J B CHEMICALS AND PHARMACEUTICALS LTD

31.19.1 COMPANY OVERVIEW

31.19.2 REVENUE ANALYSIS

31.19.3 GEOGRAPHIC PRESENCE

31.19.4 PRODUCT PORTFOLIO

31.19.5 RECENT DEVELOPMENTS

31.2 HERITAGE PHARMS

31.20.1 COMPANY OVERVIEW

31.20.2 REVENUE ANALYSIS

31.20.3 GEOGRAPHIC PRESENCE

31.20.4 PRODUCT PORTFOLIO

31.20.5 RECENT DEVELOPMENTS

31.21 HAINAN SHUANGCHENG PHARMACEUTICALS CO LTD

31.21.1 COMPANY OVERVIEW

31.21.2 REVENUE ANALYSIS

31.21.3 GEOGRAPHIC PRESENCE

31.21.4 PRODUCT PORTFOLIO

31.21.5 RECENT DEVELOPMENTS

31.22 MEITHEAL PHARMACEUTICALS INC

31.22.1 COMPANY OVERVIEW

31.22.2 REVENUE ANALYSIS

31.22.3 GEOGRAPHIC PRESENCE

31.22.4 PRODUCT PORTFOLIO

31.22.5 RECENT DEVELOPMENTS

31.23 TEVA PHARMS USA INC

31.23.1 COMPANY OVERVIEW

31.23.2 REVENUE ANALYSIS

31.23.3 GEOGRAPHIC PRESENCE

31.23.4 PRODUCT PORTFOLIO

31.23.5 RECENT DEVELOPMENTS

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

32 RELATED REPORTS

33 CONCLUSION

34 QUESTIONNAIRE

35 ABOUT DATA BRIDGE MARKET RESEARCH

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The octreotide market size will be worth USD 3.80 billion by 2030.
The growth rate of the octreotide market is 3% during the forecast period by 2030.
The robust pipeline of drugs in clinical trials is the growth driver of the octreotide market.
Type, form, indications, distribution channel, and end-user are the factors on which the octreotide market research is based.
Major companies in the octreotide market are Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), China National Pharmaceutical Group Corporation (China), Sihuan Pharmaceutical Holdings Group Ltd (China), Shanghai Soho-Yiming Pharmaceuticals Co.,Ltd. (China).

Industry Related Reports

Testimonial